<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657005</url>
  </required_header>
  <id_info>
    <org_study_id>TK216-01</org_study_id>
    <nct_id>NCT02657005</nct_id>
  </id_info>
  <brief_title>TK216 in Patients With Relapsed or Refractory Ewing Sarcoma</brief_title>
  <official_title>A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncternal Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncternal Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets
      family transcription factors driving tumor progression. TK216 is designed to inhibit this
      effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. This study is a
      first in human study of TK216 in subjects with Ewing sarcoma. The study is designed to
      establish initial safety and efficacy data in monotherapy and in combination with vincristine
      to assess the potential of TK216 for further development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is currently in the &quot;expansion&quot; phase after finding the recommended phase 2 dose in
      the dose/schedule escalation cohorts. Eighteen patients will be enrolled in the expansion
      phase. Vincristine is administered starting cycle 1, along with a 14 day continuous infusion
      of TK216.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>18 months</time_frame>
    <description>Listing of dose-limiting toxicities by daily dose in mg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>18 months</time_frame>
    <description>Maximum daily dose in mg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biologically effective and recommended Phase 2 dose (RP2D)</measure>
    <time_frame>18 months</time_frame>
    <description>Daily dose in mg/m^2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity as measured by Overall Response Rate (ORR)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity as measured by Duration of Response (DOR)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Disease Control</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assay methods to detect EWS-FLI1 (or EWS-ERG and EWS-ets)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve [AUC]</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Halflife [T1/2]</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: serum miRNA profile</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: tumor tissue RNA assays</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: tumor tissue protein assays</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Sarcoma, Ewing</condition>
  <arm_group>
    <arm_group_label>TK216 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TK216</intervention_name>
    <description>Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein</description>
    <arm_group_label>TK216 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of Ewing sarcoma (including ESFT)
             in subjects with relapsed or refractory disease who have failed standard therapy

        Exclusion Criteria:

          -  Symptomatic brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Breitmeyer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oncternal Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oncternal Information</last_name>
    <phone>858-434-1113</phone>
    <email>clinical@oncternal.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rubi Arias</last_name>
      <phone>310-794-0345</phone>
      <email>rubiarias@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Noah Federman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew O'hern, BS</last_name>
      <phone>720-777-8557</phone>
      <email>matthew.O'hern@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Margaret Macy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Winchester</last_name>
      <phone>646-888-5711</phone>
      <email>winchesm@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Leeolou</last_name>
      <phone>646-888-5717</phone>
      <email>leeoloum@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Paul A Meyers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Pennell, BSN,RN, CCRC</last_name>
      <phone>919-660-9217</phone>
      <email>jessica.pennell@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Riedel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Anderson, MD, PhD</last_name>
      <phone>216-308-2706</phone>
      <email>andersp@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Peter Anderson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Blum</last_name>
      <phone>503-494-0703</phone>
      <email>blume@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Lara Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer &amp; Hematology Centers, Baylor College</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy McCarthy, RN</last_name>
      <phone>832-824-4804</phone>
      <email>ksmccart@txch.org</email>
    </contact>
    <investigator>
      <last_name>Jodi A Muscal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph A Ludwig, MD</last_name>
      <phone>713-792-3626</phone>
    </contact>
    <contact_backup>
      <last_name>Gracy Zacharian</last_name>
      <phone>713-792-2669</phone>
      <email>gzachari@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph A Ludwig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

